BioCardia: Funding, Investors & Team (Sep 2026)
We are a company that is in the advanced stages of developing therapies for cardiovascular diseases that have not been effectively addressed by current medical options. Our company, BioCardia, is focused on creating unique regenerative medicine solutions through our CardiAMP™ and CardiALLO™ therapies. The clinical results we have obtained for these treatments are strong and are based on the most rigorous data available, using marrow-derived cells delivered directly into the heart. In addition to these therapies, we have developed our Helix™ transendocardial delivery systems and Morph® vascular access products, which can also be utilized in other potentially successful regenerative medicine treatments. These products are partnered with other programs to maximize their effectiveness.
BioCardia has raised $9.3M across 3 funding rounds on record, the most recent an undisclosed round of $4.4M announced in Jun 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
BioCardia Company Profile and Key Stats
Latest funding round on record: Jun 2026.
BioCardia Funding Rounds
BioCardia raised $3.6M in an undisclosed round announced in Dec 2022.
11 months later, an undisclosed round of $1.3M was announced in Nov 2023.
2.6 years later, an undisclosed round of $4.4M was announced in Jun 2026.
BioCardia Founders and Leadership Team
Contact details for the BioCardia team: 2 of 2 have an email address on file.
Start 14-day free trial →BioCardia Funding Compared to Other Biotechnology Startups
BioCardia's latest round of $4.4M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like BioCardia in Biotechnology and San Carlos
Companies Similar to BioCardia
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
BioCardia Funding FAQs
What does BioCardia do?
We are a company that is in the advanced stages of developing therapies for cardiovascular diseases that have not been effectively addressed by current medical options. Our company, BioCardia, is focused on creating unique regenerative medicine solutions through our CardiAMP™ and CardiALLO™ therapies. The clinical results we have obtained for these treatments are strong and are based on the most rigorous data available, using marrow-derived cells delivered directly into the heart. In addition to these therapies, we have developed our Helix™ transendocardial delivery systems and Morph® vascular access products, which can also be utilized in other potentially successful regenerative medicine treatments. These products are partnered with other programs to maximize their effectiveness.
How much funding has BioCardia raised?
BioCardia has raised $9.3M across 3 rounds on record. The most recent is an undisclosed round of $4.4M announced in Jun 2026.
When did BioCardia last raise funding?
BioCardia's most recent funding round on record is an undisclosed round of $4.4M, announced in Jun 2026.
Who founded BioCardia?
FundedIQ lists Peter Altman (Founder) at BioCardia.
Who is the CEO of BioCardia?
Peter A Altman is listed as CEO at BioCardia.
Where is BioCardia headquartered?
BioCardia is based in San Carlos, California, United States.
How many employees does BioCardia have?
BioCardia is in the 11-50 employee band.
How does BioCardia's funding compare to other Biotechnology startups?
BioCardia's latest round of $4.4M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's BioCardia Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for BioCardia is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.